Soliqua SoloStar Pens

US shipping from Canada is available for this combination injectable used in type 2 diabetes care, and this page summarizes key product facts for Soliqua 100/33 pens. It describes what the medicine contains, how the SoloStar device is used once daily, and what to know about storage and safety. It also outlines access steps for people paying cash, including those without insurance, so site actions like prescription submission are clearer.

What Soliqua Is and How It Works (buy Soliqua Solostar Pens)

Soliqua 100/33 is a fixed-dose combination of insulin glargine (a long-acting basal insulin) and lixisenatide, a GLP-1 receptor agonist. Basal insulin helps lower glucose between meals and overnight. Lixisenatide supports glucose-dependent insulin release and can slow gastric emptying (how fast food leaves the stomach), which may reduce postprandial (after-meal) glucose rises. The product is delivered as a prefilled pen designed for subcutaneous injection.

Ships from Canada to US through this site’s referral workflow. Prescription details may be verified with the prescriber when required. The combination is not intended for treating diabetic ketoacidosis, and it is not a substitute for rapid-acting mealtime insulin when that is clinically indicated. For broader background on insulin types, see Different Types Of Insulin.

Who It’s For

This medicine is generally used for adults with type 2 diabetes when glucose goals are not met on basal insulin alone or on a GLP-1 receptor agonist alone, depending on local labeling and prescriber judgment. It combines a basal insulin component with an incretin-based component in one pen, which may be considered when simplifying a regimen is a priority. For condition context and related therapies, browse Type 2 Diabetes.

It is not used for type 1 diabetes, and it is not used to treat diabetic ketoacidosis. Do not use it during an episode of low blood sugar, and do not use it if there is a known allergy to insulin glargine, lixisenatide, or another ingredient. People with a history of pancreatitis, severe gastrointestinal disease, or significant kidney impairment may need extra caution and monitoring. If reviewing eligibility and risks while planning to buy Soliqua Solostar Pens, a prescriber should confirm whether a GLP-1 product is appropriate; related class options can be browsed under GLP-1 Agonists, and practical reading is collected in Type 2 Diabetes Articles.

Dosage and Usage

Soliqua 100/33 is taken once daily as a subcutaneous injection, typically within 1 hour before the first meal of the day, per product labeling. The dose is measured in insulin units on the pen. Starting doses and titration schedules depend on prior therapy (for example, prior basal insulin dose range or prior lixisenatide use) and on fasting blood glucose trends. Dose adjustments are made gradually according to the prescribing information, and the label sets a maximum daily dose because the lixisenatide amount increases as insulin units increase.

Administration is generally in the abdomen, thigh, or upper arm, with rotation of sites to reduce lipodystrophy (changes in the fat under the skin). This medicine is injected under the skin, not into a vein or muscle, and it should not be used in an insulin pump. Do not mix it with other insulins in the same syringe, and do not share pens, even if the needle is changed.

Using the prefilled pen device

The SoloStar device is intended for single-patient use and is designed to deliver a measured dose by dialing units and pressing the injection button. A new sterile needle is typically used for each injection, and the pen is primed per the instructions before dosing to help confirm flow. After injecting, the needle is removed and discarded in a sharps container to reduce leakage and contamination. Quick tip: Keep a spare needle and alcohol swab available when traveling, along with a backup plan for missed doses from the prescriber. For general education on dosing concepts and titration discussions, see Insulin Dosage Chart and the product overview Soliqua Dual Action Guide.

Strengths and Forms

Soliqua is supplied as a prefilled pen that contains a fixed ratio of insulin glargine and lixisenatide. The commonly referenced presentation is Soliqua 100/33 (100 units/mL insulin glargine and 33 mcg/mL lixisenatide) in a 3 mL pen. Packaging and availability can vary by dispensing pharmacy and jurisdiction, so confirm the exact carton configuration during processing.

The product listing for buy Soliqua Solostar Pens reflects the prefilled pen format rather than vials or cartridges. Needles are typically not included with prefilled pens, so they may be obtained separately if needed. For related basal insulin formats, browse Long Acting Insulin.

Storage and Travel Basics

Storage directions should be checked on the carton and prescribing information for the dispensed product. In general, unopened pens are refrigerated at 2°C to 8°C and protected from light. Do not freeze, and do not use the pen if it has been frozen. Avoid exposing the pen to excessive heat, such as a parked car or direct sunlight, because both insulin and GLP-1 components can degrade with temperature extremes.

After first use, many labels direct that the pen be kept at room temperature (within the label’s stated limit) for a limited in-use period, and the pen cap should stay on when not in use. Do not store a pen with a needle attached. Orders are dispensed by licensed Canadian pharmacies. For travel, carry supplies in hand luggage, keep the prescription label with the carton, and use an insulated bag to reduce temperature swings; avoid placing the pen directly against ice packs.

Side Effects and Safety

Side effects can reflect either component. Gastrointestinal effects such as nausea, vomiting, or diarrhea may occur because of the lixisenatide component, especially when starting or titrating. Hypoglycemia (low blood sugar) can occur due to the insulin glargine component, and the risk may increase with missed meals, changes in activity, or use with other glucose-lowering medicines. Other effects can include headache, upper respiratory symptoms, injection-site reactions, or changes in appetite.

Serious risks can include severe hypoglycemia, allergic reactions, pancreatitis, kidney problems (sometimes related to dehydration from vomiting), and low potassium. Why it matters: Recognizing severe low blood sugar early can prevent injury and emergency care. Monitoring plans (glucose checks, symptom review, and follow-up timing) should be set by a healthcare professional, particularly after starting or adjusting therapy. If documenting side-effect history while planning to buy Soliqua Solostar Pens, include prior reactions to basal insulin or GLP-1 medicines; background reading on the basal insulin component is available in Insulin Glargine Overview.

Drug Interactions and Cautions

Many medicines can affect blood glucose or how symptoms are perceived. Other diabetes medicines (such as sulfonylureas or prandial insulin) may increase hypoglycemia risk when combined with basal insulin, and clinicians may adjust the overall regimen. Beta-blockers can mask some adrenergic warning signs of low blood sugar. Corticosteroids and some antipsychotics can raise glucose and may complicate dose titration.

Because lixisenatide can slow gastric emptying, it may change absorption of certain oral medicines; the label provides guidance for time-sensitive drugs. Combination with other GLP-1 receptor agonists is generally avoided, and this product is not typically used alongside another basal insulin product. If medication reconciliation is being prepared for buy Soliqua Solostar Pens, include over-the-counter products and alcohol use, since both can affect glucose patterns. For a structured overview of basal insulin precautions and common interaction themes, see Lantus Side Effects.

Compare With Alternatives

Fixed-dose basal insulin/GLP-1 combinations are one approach for adults with type 2 diabetes who need both fasting and after-meal support. Another fixed-ratio option is insulin degludec/liraglutide, available as Xultophy Prefilled Pen. Basal insulin alone (without a GLP-1 component) is also commonly used and may be paired with separate non-insulin therapies when appropriate.

Comparisons often involve dosing schedules, titration flexibility, tolerability, and contraindications. For example, basal-only regimens may have fewer GI effects but may not address post-meal glucose as directly as a GLP-1–containing regimen. A commonly used basal insulin pen is Lantus SoloStar Pens, which contains insulin glargine without lixisenatide. Switching between therapies should follow the official prescribing information and prescriber guidance, since starting doses and monitoring needs differ.

Pricing and Access

Pricing depends on the dispensed package size, pharmacy sourcing, and prescription requirements, and totals can differ between people paying out of pocket and those using coverage. The service supports cash-pay access for people without coverage. CanadianInsulin operates as a prescription referral service, and partner pharmacies dispense approved orders after required documentation is received.

For site actions related to buy Soliqua Solostar Pens, be prepared to provide a valid prescription and prescriber contact information so verification can be completed when needed. People managing therapy without insurance may also want to keep a current medication list and recent glucose records ready for their prescriber, since dose titration depends on measured trends. To browse related diabetes therapies by class, use the Diabetes category hub.

Authoritative Sources

For official labeling, indications, and detailed warnings, consult the regulator-approved prescribing information. A neutral starting point is the FDA product record for Soliqua 100/33: FDA Drugs@FDA Application Overview.

Device steps and storage limits can vary by label version and region, so the carton insert and pharmacy-provided leaflet should be treated as the primary instructions for the dispensed pen. Clinicians can also confirm whether co-administered diabetes medicines should be adjusted during initiation and titration.

To submit an order for dispensing, complete the intake steps and select prompt, express, cold-chain shipping when available.

This content is for informational purposes only and is not a substitute for professional medical advice.